Key Takeaways
- • Rep. Steve Cohen (D-TN) introduced the Public Health and Research Reforms in Controlled Substances Act, described as the most sweeping rewrite of the 1970 Controlled Substances Act, and the bill removes marijuana from the CSA entirely rather than rescheduling it.
- • The bill eliminates weight-based mandatory minimum drug penalties and directs the U.S. Sentencing Commission to revise guidelines with retroactivity, so reforms would reach people already sentenced.
- • Scheduling authority would shift from the Attorney General and DEA to the Secretary of Health and Human Services, which would also handle researcher registrations and production quotas, with new blanket research licenses created.
- • About 30 substances, including fentanyl, morphine, methamphetamine, psilocybin and ibogaine, are first in line for review under new schedules, and none would be descheduled.
- • The bill is endorsed by the Drug Policy Alliance, NORML, MAPS and Students for Sensible Drug Policy, and is Cohen's 500th sponsored bill, as reported by stupidDOPE.
Summary
Representative Steve Cohen of Tennessee, a senior member of the House Judiciary Committee, has introduced the Public Health and Research Reforms in Controlled Substances Act, according to stupidDOPE. The measure is the 500th piece of legislation Cohen has sponsored since entering Congress. Its central cannabis provision removes marijuana from the Controlled Substances Act entirely, a more complete step than moving the drug to a lower schedule. For the legal cannabis industry, which operates in most states while remaining federally prohibited, removal would end that conflict at the statutory level rather than through agency rescheduling that can be litigated or reversed.
The bill revises nearly every section of the 1970 law across six titles. It eliminates weight-based mandatory minimum drug penalties while preserving judicial sentencing discretion and enforcement against major narcotics traffickers. The U.S. Sentencing Commission is directed to account for these changes and provide for retroactivity. Cohen said in his statement that "a thoughtful review of national drug policy is long overdue." Sia Henry of MAPS praised the removal of mandatory minimums and retroactive application as a first step.
The structural core of the bill transfers scheduling authority from the Attorney General and the DEA to the HHS Secretary, who would also set production quotas and issue researcher registrations, while the DEA would focus on diversion and illicit use. A statutory factor analysis, reviewed by an external advisory committee, is intended to make scheduling decisions transparent. The bill creates blanket controlled substances research licenses, strengthens research language in the 2025 HALT Fentanyl Act, corrects the definition of a controlled substance analogue, and updates emergency scheduling. It also expands White House Office of National Drug Control Policy coordination first authorized in the SUPPORT Act.
Rather than leaving the five-schedule structure intact, the bill creates new, more granular schedules and requires review of all controlled substances against them. About 30 compounds, including fentanyl, morphine, methamphetamine, psilocybin and ibogaine, are first in line, with none set to be descheduled. Eric E. Sterling, who served as counsel to the House Judiciary Committee from 1979 to 1989, said the need to modernize the CSA "has long been apparent."
The bill faces long odds in any Congress, as stupidDOPE notes, and no change in federal status occurs on introduction. Still, it presents the most complete alternative to the 1970 framework in legislative form, along with a section-by-section analysis and a companion explanatory document for future Congresses. Cohen's office has published the full announcement.
The bill revises nearly every section of the 1970 law across six titles. It eliminates weight-based mandatory minimum drug penalties while preserving judicial sentencing discretion and enforcement against major narcotics traffickers. The U.S. Sentencing Commission is directed to account for these changes and provide for retroactivity. Cohen said in his statement that "a thoughtful review of national drug policy is long overdue." Sia Henry of MAPS praised the removal of mandatory minimums and retroactive application as a first step.
The structural core of the bill transfers scheduling authority from the Attorney General and the DEA to the HHS Secretary, who would also set production quotas and issue researcher registrations, while the DEA would focus on diversion and illicit use. A statutory factor analysis, reviewed by an external advisory committee, is intended to make scheduling decisions transparent. The bill creates blanket controlled substances research licenses, strengthens research language in the 2025 HALT Fentanyl Act, corrects the definition of a controlled substance analogue, and updates emergency scheduling. It also expands White House Office of National Drug Control Policy coordination first authorized in the SUPPORT Act.
Rather than leaving the five-schedule structure intact, the bill creates new, more granular schedules and requires review of all controlled substances against them. About 30 compounds, including fentanyl, morphine, methamphetamine, psilocybin and ibogaine, are first in line, with none set to be descheduled. Eric E. Sterling, who served as counsel to the House Judiciary Committee from 1979 to 1989, said the need to modernize the CSA "has long been apparent."
The bill faces long odds in any Congress, as stupidDOPE notes, and no change in federal status occurs on introduction. Still, it presents the most complete alternative to the 1970 framework in legislative form, along with a section-by-section analysis and a companion explanatory document for future Congresses. Cohen's office has published the full announcement.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.